During the last session, Oragenics Inc. (AMEX:OGEN)’s traded shares were 3.11 million, with the beta value of the company hitting 0.27. At the end of the trading day, the stock’s price was $0.80, reflecting an intraday loss of -5.11% or -$0.04. The 52-week high for the OGEN share is $2.09, that puts it down -161.25 from that peak though still a striking 52.5% gain since the share price plummeted to a 52-week low of $0.38. The company’s market capitalization is $93.29M, and the average intraday trading volume over the past 10 days was 3.51 million shares, and the average trade volume was 6.24 million shares over the past three months.
Oragenics Inc. (OGEN) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. OGEN has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.04.
Oragenics Inc. (AMEX:OGEN) trade information
Oragenics Inc. (OGEN) registered a -5.11% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -5.11% in intraday trading to $0.80 this Wednesday, 06/09/21, hitting a weekly high. The stock’s 5-day price performance is 12.60%, and it has moved by 25.72% in 30 days. Based on these gigs, the overall price performance for the year is 27.55%. The short interest in Oragenics Inc. (AMEX:OGEN) is 2.62 million shares and it means that shorts have 0.72 day(s) to cover.
Oragenics Inc. (OGEN) estimates and forecasts
Statistics show that Oragenics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Oragenics Inc. (OGEN) shares have gone up 74.59% during the last six months, with a year-to-date growth rate more than the industry average at 57.45% against 9.00. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 83.30% this quarter and then jump 37.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.10%. While earnings are projected to return -27.00% in 2021.
Oragenics Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Oragenics Inc. (AMEX:OGEN)’s Major holders
Oragenics Inc. insiders own 2.74% of total outstanding shares while institutional holders control 9.04%, with the float percentage being 9.30%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 30 institutions own stock in it. As of Mar 30, 2021, the company held over 4.52 million shares (or 3.91% of all shares), a total value of $4.1 million in shares.
The next largest institutional holding, with 1.58 million shares, is of Blackrock Inc.’s that is approximately 1.37% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $1.43 million.
Also, the Mutual Funds coming in first place with the largest holdings of Oragenics Inc. (OGEN) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 3.55 million shares. This amounts to just over 3.07 percent of the company’s overall shares, with a $3.22 million market value. The same data shows that the other fund manager holds slightly less at 0.81 million, or about 0.70% of the stock, which is worth about $0.74 million.